Spero Therapeutics, Inc.
SPRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001701108
In the last 90 days, Spero Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:21 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Jan 10, 2025 | Jan 5, 2024 | Jan 9, 2023 | Mar 31, 2022 |
| Revenue | $66.8M | $48.0M | $103.8M | $53.5M | $18.3M |
| Operating expenses | $60.5M | $121.3M | $82.3M | $95.7M | $106.2M |
| Research and development | $38.5M | $96.8M | $51.4M | $47.6M | $64.5M |
| Selling, general and administrative | $21.2M | $23.7M | $25.6M | $36.5M | $41.7M |
| Operating income | $6.31M | -$73.4M | $21.5M | -$42.2M | -$88.0M |
| Income tax | $261.0K | $0 | $2.60M | $0 | $0 |
| Net income | $8.57M | -$68.6M | $22.8M | -$46.4M | -$89.8M |
| EPS, basic | $0.15 | $-1.27 | $0.43 | $-1.23 | – |
| EPS, diluted | $0.15 | $-1.27 | $0.43 | $-1.23 | – |
| Weighted shares, basic | 56.0M | 54.0M | 52.7M | 37.6M | – |
| Weighted shares, diluted | 59.0M | 54.0M | 53.0M | 37.6M | – |
| Margins and growth | |||||
| Operating margin | 9.5% | -152.9% | 20.7% | -78.9% | -481.9% |
| Net margin | 12.8% | -142.9% | 22.0% | -86.7% | -491.9% |
| Revenue growth, year over year | +39.2% | −53.8% | +94.0% | +193.1% | +95.7% |
| Net income growth, year over year | – | −400.6% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Jan 10, 2025 | Jan 5, 2024 | Jan 9, 2023 | Mar 31, 2022 |
| Cash and equivalents | $40.3M | $52.9M | $76.3M | $109.1M | $112.6M |
| Short-term investments | – | – | – | $0 | $33.8M |
| Total current assets | $67.3M | $107.3M | $131.2M | $113.6M | $157.9M |
| Property, plant and equipment | – | $0 | $2.00K | $368.0K | $1.03M |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M |
| Accounts payable | $693.0K | $7.31M | $1.38M | $617.0K | $1.10M |
| Total current liabilities | $8.87M | $49.1M | $37.2M | $21.6M | $18.7M |
| Total liabilities | $9.90M | $64.4M | $75.5M | $48.9M | $82.8M |
| Shareholders' equity | $59.0M | $46.1M | $106.9M | $75.9M | $88.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Jan 10, 2025 | Jan 5, 2024 | Jan 9, 2023 | Mar 31, 2022 |
| Operating cash flow | -$12.6M | -$23.4M | -$33.0M | -$7.73M | -$64.3M |
| Depreciation and amortization | $0 | $2.00K | $367.0K | $869.0K | $646.0K |
| Stock-based compensation | $4.33M | $7.79M | $7.93M | $9.12M | $9.43M |
| Investing cash flow | – | – | $0 | $33.8M | $7.67M |
| Financing cash flow | – | $0 | $221.0K | -$29.6M | $84.0M |
| Net change in cash | -$12.6M | -$23.4M | -$32.8M | -$3.48M | $27.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 6.5% | 16.2% | 7.6% | 17.0% | 51.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 58.3M | +3.4% | SEC |
| Aug 7, 2026 | 58.2M | +3.5% | SEC |
| May 1, 2026 | 57.9M | +3.6% | SEC |
| Mar 20, 2026 | 57.9M | +3.6% | SEC |
| Nov 6, 2025 | 56.3M | +3.3% | SEC |
| Aug 5, 2025 | 56.3M | +4.1% | SEC |
| May 1, 2025 | 55.9M | +3.6% | SEC |
| Mar 21, 2025 | 55.9M | +3.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.